Wed, Apr 16, 2014, 3:31 PM EDT - U.S. Markets close in 29 mins.

Recent

% | $
Quotes you view appear here for quick access.

Genomic Health Inc. Message Board

  • stupid_hobo73 stupid_hobo73 Feb 8, 2012 10:34 AM Flag

    analysts....

    ....apparently don't like the the earnings hit GHI will take as a result of the new subsidiary....S&P lowers to "hold" and lowers price target by $2 to $29.

    *********************************************

    02/07/12 10:28 am ET ... S&P LOWERS RECOMMENDATION
    ON SHARES OF GENOMIC
    HEALTH TO HOLD FROM BUY (GHDX 27.40***):
    Q4 EPS of $0.08, vs. $0.06, is $0.02 below our
    previously published Capital IQ consensus EPS
    estimate. Sales grew 15%, in line with consensus,
    on solid growth of GHDX's oncotype breast
    cancer test.We see continued solid sales of
    the oncotype test on increasing worldwide reimbursement
    and an expanding sales force.
    GHDX guides 2012 net income, inclusive of an
    investment in a new genetics subsidiary, of
    breakeven to a $3M loss, or $0.00 to a $0.10
    loss. Capital IQ's consensus forecast has been
    lowered $0.47 to a loss of $0.04.We are reducing
    our target price by $2 to $29.
    *****************************************

    short run hit to the stock but longer term the company is growing, building, expanding.....great stock to grow capital, net worth....

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Note the target is $29.The volume is good and I bought more this morning.I suspect I am in competition with the Baker Bros.As I have posted in the past,I believe Kim and the gang want to stay single and build great science company.Unfortunately when you become successful as GHDX has, you become prey.Look at the Baker Bros largest holding last year(Pharmasset).then... Gilead Sciences buys Pharmasset for an astounding amount.I am not saying revenues will approach the hep C market but strong steady growth and good science make GHDX very attractive.

      • 1 Reply to rosemariecorbin
      • so when GHDX traded at $29.50 a few days ago and S&P had a $31 price target, it was a "buy" but now at $26 with a $29 price target it is a "hold"....or in other words, a potential $1.5 upside (+5%) was worthing buying but a potential $3 upside (+11.5%) is not worth buying ?!?

        I am just kidding of course....Old Wall St is broken....analysts are in a lose/lose situation....most are way behind the curve and their comp plans don't help....

        But that said, let's see if S&P steps up and upgrades 36 hours after downgrading....I'm guessing 'no'...

 
GHDX
26.57-0.84(-3.06%)3:31 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.